# A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

> **NCT02688933** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 638 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** HOE901-U300 (Insulin Glargine 300 U/ml)
- **DRUG:** Lantus (Insulin Glargine 100 U/ml)
- **DRUG:** Mandated back ground therapy

## Key facts

- **NCT ID:** NCT02688933
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-05
- **Primary completion:** 2017-06-19
- **Final completion:** 2017-06-19
- **Target enrollment:** 638 (ACTUAL)
- **Last updated:** 2022-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02688933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02688933, "A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02688933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*